Summary:
- Researchers have developed a new compound that is similar to LSD but without the hallucinogenic effects. This compound, called NORIBOGAINE, has the potential to treat schizophrenia and other mental health conditions.
- The study found that NORIBOGAINE can target specific receptors in the brain that are involved in schizophrenia, without causing the psychedelic effects associated with LSD.
- Further research is needed to determine the safety and effectiveness of NORIBOGAINE as a treatment for schizophrenia, but this discovery offers a promising new approach to addressing this complex mental health condition.